Tumor suppressor genes in familial adenomatous polyposis

Nahal Eshghifar1, Naser Farrokhi2, Tahereh Naji1, Mohammad Reza Zali3

1 Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences & Technology, Pharmaceutical Science Branch, Islamic Azad University, Tehran, Iran
2 Department of Plant Biology & Biotechnology, Faculty of Life Sciences & Biotechnology, Shahid Beheshti University G.C., Tehran, Iran
3 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Colorectal cancer (CRC) is mostly due to a series of genetic alterations that are being greatly under the influence of the environmental factors. These changes, mutational or epigenetic modifications at transcriptional forefront and/or post-transcriptional effects via miRNAs, include inactivation and the conversion of proto-oncogene to oncogenes, and/or inactivation of tumor suppressor genes (TSG). Here, a thorough review was carried out on the role of TSGs with the focus on the APC as the master regulator, mutated genes and mal-functional pathways that lead to one type of hereditary form of the CRC; namely familial adenomatous polyposis (FAP). This review provides a venue towards defining candidate genes that can be used as new PCR-based markers for early diagnosis of FAP. In addition to diagnosis, defining the modes of genetic alterations will open doors towards genome editing to either suppress the disease or reduce its progression during the course of action.

Key words: Familial adenomatous polyposis (FAP), Tumor suppressor genes (TSGs), Adenomatous polyposis coli (APC)


Introduction

Colorectal cancer (CRC) with almost one million new incidences each year is classified amongst aggressive malignancies. Among people with CRC, about 10% have a first-degree affected relative(s) with the disease (1), (2) and more than half of the gastrointestinal tract cancers are linked to diet (3), (4). CRC appears in many shapes and forms (5) and here familial adenomatous polyposis (FAP) that accounts for about 1% of CRC cases is going to be reviewed due to its general occurrence in earlier stages of life.

Common FAP, Gardner syndrome, desmoids and attenuated FAP are all different forms of FAP (5-9). As the name suggests, numerous polyps and growth of the inner lining, are being formed in the colon and rectum (Figure 1). Most polyps are benign; however some polyps may advance to cancer (9-11). Similar to other cancers, FAP is the result of a series of genetic changes, including activation of oncogenes or inactivation of tumor suppressor genes (TSGs). Varieties of gene mutations and epigenetic variations in oncogenes and TSGs in addition to chromosomal changes may lead to FAP (10, 11). Mutations in TSGs lead to cell proliferation, avoiding programmed cell death. Consequently, in the absence of tumor suppressor proteins, cells, so-called “no brakes” begins their stunted growth. Chromosomal deletions bearing in APC, DCC and P53 (10, 12, 13) have also corroborated with inactivation of TSGs (10, 12-15).

Identification of new TSGs and their characterization remains an active area of cancer studies (16). In general TSGs, a suite of usually co-expressed genes and most often co-localized proteins, happened to have particular defined roles in certain cellular pathways (12, 17). The TSGs with more pronounced effects on FAP are presented in Table 1 (10,15, 16, 18-25).

Correspondence: Naser Farrokhi. Ph.D.
Address: Department of Plant Biology & Biotechnology, Faculty of Biological Sciences & Biotechnology, Shahid Beheshti University, Evin, Tehran, Iran.
Email:n_farrokhi@sbu.ac.ir
TSGs and their relevant mutation in FAP and epigenetic alterations and the role of miRNAs were discussed.

FAP TSGs and the corresponding mutations

Genetic mutation shall be considered as the main factor that leads to the development of FAP. Studies of mutations are important from the perspective of molecular diagnostic, treatment, and more recently for genome editing purposes (27, 28). CRCs appear in two major forms, namely sporadic and hereditary (27-29). Mutations in TSGs contribute to the progression of m cancer by inactivating their inhibitory function. Mutations in TSGs are recessive at the level of an individual cell. Normally, a single mutation in one gene for malignant phenotype is not enough and more mutations required for carcinogenesis (10, 20, 28).

Among the early events in the FAP tumor progression pathway is the lack of the APC gene, a TSG, which appears to be consistent with its essential role in predisposing individuals with germ line APC mutations in colorectal tumors. Mutations within the APC, more than 300 mutations, have correlated with the onset of FAP. Once APC is mutated, tumor development is unavoidable (9, 10, 30). APC is being inherited in an autosomal dominant pattern, which implies one copy of the altered gene would be adequate for cancer formation. In addition, a mutation of APC must be followed by other mutations in some genes such as other TSGs to develop into cancer (31, 32).

Mutant form of APC is found in sporadic and some types of hereditary CRC. Genetic transformation of mutant APC in FAP results in abnormal CRC cell proliferation, leading to the outgrowth of numerous adenomas in the colons of patients. Most of APC mutations are frame-shift mutations (33, 34) and population analyses have revealed the role of APC is indispensable in FAP formation (33-37). Based on many surveys (35, 38, 39), deletions at the codons 1309 (c.3927_3931delAAAGA) and 1061 (c.3183_3187delACAAA) were found to be the most frequent germ line mutations (35, 38, 39). The frequency of the first mutation differs from 0% in northern parts of Spain to 1.5% in an Israeli population and 8.4% for Australian FAP patients. The frequency of the second mutation varies from 16% in Italian, 7% in the Israeli population, 5% for Dutch, 0% in southwest of Spain, and 2.4% for Australian FAP patients (40, 41). More than 60% of APC mutations are observed within the mutation cluster region (MCR) between codons 1284-1580 or 1284–1464 (42, 43). Large rearrangements are more plausible to provide a classic FAP; while splicing mutations tend to result in attenuated FAP (AFAP) (44, 45). In a study on Greeks (44), two different cases of FAP families carrying two unusual APC mutations were observed: a splice site mutation on the fifth nucleotide of intron nine and a large genomic deletion in chromosome five. A diverse germ line–somatic APC mutation association was seen in FAP desmoids (44). Analysis of the APC in a Greek cohort (46) revealed 18 different germ line mutations (80%), distributed between exon 3 and codon 1503 of exon 15, while large genomic rearrangements were not identified (46). Additionally, a study in the Balearic Island indicated that the hotspot c.3183_3187delACAAA mutation has a significant effect on FAP (47). Few reports (44, 48) of mutations at position +5 in APC have shown that replacement of the +5 conserved nucleotide at the splice donor region of intron 9 within the APC provide frameshift and inefficient exon skipping (44, 48). Another study among the Iranian population (49) showed the detection rate of large fragment deletions in APC was 5.8% (2/34) and patients had deleted in the middle and at the end of exon 15. Comparison of clinical observations between patients without deletion and with the large deletion did not show any considerable difference in each variable, including signs of disease, age at diagnosis, and polyt type. It seems that exon 15 of APC gene is likely the hotspot zone in Iranian FAP patients (49). In a study of APC in 300 unrelated polish families with FAP, 97 types were recognized in 164 families; 80 small mutations and 17 large rearrangements, eight of which repeat rearrangements (40).

In fact, it seems that APC is part of many different signaling pathways that makes it a perfect target for mutation in FAP. Different types of mutation in the APC in FAP patients from different populations have presented in Table 2 (39, 40, 46, 47, 50-58). Altogether, it seems that the vast majority of APC mutations are small insertions/ deletions or point mutations. Splicing mutations rearrangements are less common inactivating events of the APC gene. M of 60% of APC mutations were described in exon 15. FAP patients usually harbor mutation at 5′ (codons 78-167) and 3′ (codons 1581-3843) regions of the APC (50, 59-61).

APC plays an important role in the Wnt signaling pathway. APC regulates the deprivation of β-Catenin, a transcription factor for proliferative genes, and its mutation leads to the accumulation of β-Catenin (62-64). The Wnt signaling pathway is remarkable in many cancers including FAP (65).

In addition, mutation or deletion of DCC and p53 and loss of cadherin leads to metastasis. The mutations within the P53 lead to failure of apoptotic mechanisms and change in the regulation of cell proliferation, thereby causing genomic instability and malignant development. Clarification of candidate FAP biomarkers typically commences by examining the expression profiles of normal and cancerous tissues by performing high throughput gene expression profiling. Molecular markers in FAP such as mutations, genetic instability, and protein expressions have been shown to significantly influence the disease progression (15, 17, 59, 60).

Genetic instability (GI) and chromosomal instability (CIN)

Genetic instability (GI) is associated with gene expression alterations (66). Analysis of transcripts as biomarker(s)
allows predicting the process of cancer formation using GI as an indicator (21). Approximately 70–85% of CRCs develop via chromosome instability (CIN) pathway (Figure 2) (26). CIN is defined to be one of the driving forces that stimulate tumorigenesis in FAP (15, 17, 67, 68). Changes in chromosome number (aneuploidy) and high frequency loss of heterozygosity (LOH) are associated with CIN. It can result from defects in chromosomal dissociation, failure to respond properly to DNA damage, and telomere stability (69). Accumulations of numerical or structural chromosomal abnormalities lead to CIN pathway molecular aberrations (70-72).

CIN and TSGs are somewhat associated; CIN results from a series of genetic alternation in APC, DCC, P53 and SMAD4 (14, 17, 70). Multiple uncommon inactivating mutations of genes, the ones that their normal roles are to maintain CIN throughout replication, are evident. Aggregation of these mutations account for most CINs in FAP (26, 33).

Wnt pathway

Wnts are glycoproteins where secretion is controlled particularly by a transmembrane protein, namely Wntless. Also the production of active Wnt needs a functional retromer that is a multiprotein complex involved in intracellular protein trafficking (73, 74). The Wnt signaling pathway has been reported of being altered in 93% of tumors, such as activating mutations of CTNNB1 or biallelic inactivation of APC in 80% of FAP cases. The earliest genetic event in FAP is the activation of Wnt signaling via the genetic disruption of APC (32, 33). Activation of this pathway does not, by itself, lead to cancer, but it has a remarkable role in initiating the carcinogenic mechanism. Inherited mutations in APC, as in FAP, cause the improvement of non-invasive colonic adenomas (thousands of polyps) (19). Canonical Wnt signaling pathway has an essential role in the homeostasis of the colonic epithelium and its deregulation in CRC and more specifically in FAP. APC plays a central role suppressing the canonical Wnt signaling pathway that controls cell proliferation and differentiation in the intestine (65). Wnt signaling (Figure 3) (75) regulates growth, differentiation and apoptosis and is specifically relevant in maintaining tissue specific stem cell compartments. Wnt factor binds to cell surface Frizzled (FZD10) receptor (the Wnt receptor frizzled was overexpressed that activates disheveled (Dvl) in human through the activation of casein kinases. This inhibits the activity of a multiprotein complex consisting of β-Catenin, Axin, APC and glycogen synthase kinase (GSK-3b). Normally this complex phosphorylates β-Catenin and thereby it is subjected to ubiquitination and proteosomes-mediated degradation (74, 76).

In the absence of Wnt signaling, the β-Catenin accumulates within the cytoplasm and then moves to the nucleus to make complexes with T-cell factor (TCF). TCF1 is a transcriptional target of the TCF/β-Catenin complex and could provide a negative feedback mechanism for the complex (35, 64, 77-79). Subsequently, cMyc and other genes essential for unremitting cell cycle events are being up-regulated. These genes are normally important for differentiation and stem cell renewal, but when inappropriately expressed at high levels, they can cause FAP (35, 80-82). The protein β-Catenin associated with other components is responsible for the activation of many genes, especially cMyc, responsible for inducing uninhibited cell cycle events. Increment of functional mutations in β-Catenin (CTNNB1) were diagnosed in half of the CRC tumors with intact APC, reflecting the significance of the Wnt pathway (17, 65).

Altogether, it seems that, the most commonly mutated gene in Wnt pathway in FAP is the APC. Other genes associated with a Wnt pathway are listed in Table 3 (15, 64, 65, 77-85).

The role of epigenetic modifications of TSGs in FAP

In addition to genetic mutations, epigenetic modifications determine physiological and pathological cellular functions. Human cancers “such as FAP” harbor some of different heritable abnormalities in gene expression that are not resulting from mutation in any region of the genome, named epigenetic alterations (86). Epigenetics is described as heritable alterations in gene expression without DNA mutation and encompass three classifications: DNA methylation, histone and chromatin modification, and microRNA (miRNA) changes (69, 86-88).

Changes in DNA methylation patterns may lead to FAP. DNA hyper-methylation takes place at specific regulatory sites within the promoter regions or repetitive sequences. Methylation within the CpG islands of the TSG promoters can result in transcription blockage and therefore leading to cancer (89-91). Mechanisms related to gene inactivation, such as transcriptional silencing via promoter hyper-methylation, might play a role in loss of APC function in those tumors.

Methylation of APC has been represented in a subset of colorectal tumors (92, 93), but the exact role and density of this alteration, its functional consequences, and its tumor distribution need to be addressed in future. Subsequent to APC methylation, other APC pathway components can also be influenced (20). β-Catenin is a crucial downstream part of the APC pathway and APC promoter methylation may reduce its abundance (20).

The reports on methylation is rather contradictory in FAP; in a study by Zhang, et al (94) among FAP families, hyper-methylation was observed in tumor tissues once compared to normal tissues. In contrast, in a study by Segditsas, et al. (95) indifference in methylation behavior between the two tissue samples were noted (94, 95). So far, all studies insinuate that even though APC promoter methylation has taken place early throughout colon neoplastic development, it does not result in whole gene inactivation or act as a “2nd hit” and promoter-specific modifications of APC seldom leads to
Another type of epigenetic modification is histone and chromatin changes. Histones are alkaline proteins that function as scaffolds around which DNA winds in structures known as nucleosomes. Histones have protein tails that suppress gene transcription when specific methylation and acetylation arise. Post-transcriptional alterations, such as methylation, acetylation and phosphorylation are common events that adjust the biology of histones. Some histone proteins have already been determined to be overexpressed in different types of colon tumors (90, 97, 98). It has become obvious over the past two decades that epigenetic changes of the chromatin, especially the chromatin components in the promoter areas of TSGs, play remarkable roles in pathogenesis (90).

While there may be some understanding of how such genetic and epigenetic changes may affect the gene expression, and thereby tumor evolution, it is less clear how these mechanisms may have an effect on each other, and how these cumulative changes may coevolve and have an impact on gene expression inside the route of tumorgenesis (99).

Genomic imbalance and DNA methylation have been shown to disrupt normal gene expression and gene dosage, whereas disruptions of DNA methylation profiles may play a function in genomic instability especially at repeat-rich sequences.

Even though relatively less is known in regards to the patterns of particular histone alterations in FAP, selective histone alterations and resultant chromatin conformation have been shown to act in coordination with DNA methylation to adjust gene expression to mediate FAP pathogenesis. Furthermore, it is now clear that not only DNA methylation but also histone alterations are reversible tactics. Better comprehension of epigenetic regulation of gene expression within the context of pathogenesis has led to progress of epigenetic biomarkers for FAP diagnosis and epigenetic medications for FAP therapy (90, 99).

**MiRNA**

MiRNAs are short noncoding RNA sequences (19 to 25 nucleotides), which are involved in various biological processes such as cell death, differentiation and proliferation (100, 101). They induce gene suppression up to 30% (102). Modified miRNA expression has been reported in genes associated with FAP and specific miRNA patterns have described certain CRCs (86, 90).

MiRNAs are encoded within the genome, transcribed into forerunner transcripts, and undergo a series of strongly regulated processes leading to their incorporation in the RNA-inducing silencing complex (RISC). Thus, RISC directs the modulation of miRNAs translation by way of the binding of the miRNA to the 3’ untranslated area of the target mRNA via a regional or whole sequence homology; accordingly, the translation of the miRNA would be down regulated or blocked, respectively (102-104).

Staphylococcal nuclease Tudor domain containing 1 (SND1) is a novel part of RISC in RNA-interference (RNAi) process. SND1 has been reported to be overexpressed in FAP and also in models of colon cancer. Overexpression of SND1 can effect on activation of the Wnt-β-Catenin pathway via down regulation of the APC. Given the fact that SND1 influences the onset of FAP via miRNA-mediated gene silencing, more researches are needed to further define how SND1 lead to FAP (105, 106).

The role of miRNA in regulation of APC expression is another topic of interest. So far, target sequences for miRNA as well as the location of three encoding genes were recognized. The STAB1 coding miR-135a-1 is located in 3q21 (first intron of the stabilin 1), while the RMST coding miR-135a-2 is in intron 5, coding the transcript related to rhabdomyosarcoma (12q23) (107). Experimentally was shown that miR135a and miR135b interact with 3’UTR transcript of the APC, affecting the abundance of relative mRNA. Therefore, APC expression is being regulated and as a result the Wnt proliferation control signaling pathway. Increased levels of miR-135a and miR-135b caused the reduction in the APC mRNA abundance (10, 107). MiRNAs have been linked to many levels of cancer, from initiation and development of tumors in response to treatment, and development of new therapies. Lately, the role of altered miRNA expression in the Wnt pathway regulation and FAP advancement was also been evaluated. The studies inferred the decreased expression of miR-20b, miR-126, miR-143, and miR-145 as a primary event of FAP tumors (108, 109). It has been suggested that there is also a complex interaction amongst the various epigenetic changes, particularly after silencing of tumor suppressive miRNAs with the aid of promoter CpG methylation used to be suggested (110).

**Current Diagnostic Methodologies for FAP**

Multiplex ligation-dependent probe amplification (MLPA) (111) is commonly used for the concurrent evaluation of gene dosage and this technique is used to find exonic duplications and deletions with APC. MLPA is being considered as the first appropriate step in the analysis of a suspicious FAP cases. The relative analytical ease of MLPA versus the full gene scanning and the relative frequency of genomic rearrangements both justifies the use of MLPA. It needs to be stated that the present commercially MLPA kits have not yet been confirmed for diagnostic purposes (49, 112).

Cytogenetic analysis/ de novo and translocations disrupting APC, and inherited deletions that can be detectable cytogenetically were recognized in a small number of families/ individuals. Also, chromosome investigations could be considered, if no mutations were detected (6, 19, 112).

In cases where the mutation is evident, it is more likely that the individual develops FAP. Since APC mutations are nearly 100% penetrant, their onset most likely will develop...
into FAP. On the other hand, individuals with no familial mutation signifies that the development of FAP is highly unlikely. However, reports should point out that they continue to be at populace risk of sporadic CRC (34, 112). Prenatal testing and pre-implantation genetic diagnosis (PGD) is not often asking for FAP, but has been performed on a number of occasions (112).

Next generation sequencing (NGS) technology could be included as an appropriate diagnostic technique for the recognition of intragenic mutation testing of FAP. The multiplex NGS approach has the benefit of analyzing numerous genes in numerous samples, bearing the fact that technology is becoming more cost-effective as time goes by. Furthermore, with technology development the diagnostic turnaround times have been reduced immensely and continues to be further declined (113, 114, 115). The other main advantage of NGS is its capability to define the relevant genes that have remained elusive (116).

Pre-symptomatic testing (117), APC exon dosage analysis such as microsatellite analysis (112), exon-specific qPCR, linked SNP (112), cytogenetic FISH analysis (112, 118) and/or karyotyping array CGH or Southern analysis with cDNA probes (111, 112) would be the other techniques. However, these methodologies usually are not in common use (34, 112, 119).

Discussion

Most FAP cases are resulting from germ line mutations in APC. Mutations are located mainly at the 5' end, but extend all over the length of the APC. Most of which are small deletions/insertions or point mutations, and most result in N-terminus of protein fragments failing the protein in binding and degradation of β-Catenin and consequently cannot suppress Wnt/β-Catenin pathway (34, 120).

Several studies have failed to correlate the lack of APC with activation of the Wnt pathway as determined by the presence of nuclear β-Catenin, especially in early adenomas (121-123). An absence of nuclear β-Catenin suggests involvement of other factors such as methylation. Taken together the studies declare that epigenetic changes cooperate with proliferative signals for initiation and development of colon tumors (124). Usually, most mutations are positioned in exon 15 of APC due to the fact it is the largest known exon (6557 bp long). Additionally, promoter hyper-methylation and loss of heterozygosity of APC has been reported in FAP and CRC (10, 17, 35, 125). Lack of APC, seems to induce improper DNA methylation.

These modifications in DNA methylation, along with alterations in histone modifications, create a new perspective to explain failures in cell signaling and onset of FAP and other types of CRCs. Currently, some of causal mutations in FAP patients could not be diagnosed in APC and other polyposis-relevant genes such as MUTYH (34, 109, 126). Epigenetic cancer markers are just beginning to be understood, but are being inquired for use in early detection and prognosis, tumor classifications, following the effectiveness of chemotherapy, and providing targets of intervention. In précis, colon cancer genetics has organized genetic testing for hereditary syndromes and guides to therapy with obtained mutations, while epigenetic mechanisms have the ability of being vital to many regions of cancer diagnosis and therapy.

It seems that, studies that aid in understanding of FAP on a molecular level have produced significant tools for genetic testing for high-risk hereditary of the disease, predictive markers. From the evidence, we can infer that many genes (whether tumor suppressor or oncogenes) do have an impact on inherited diseases such as FAP.

Also, they could have significant roles on many pathways that associated with the disease (19, 127, 128). As an effective high-throughput tool, NGS would possibly replace current screening strategies for polyposis. Last but not least, future studies will help to describe whether special epigenetic perspectives would be necessary and allow transformation by oncogenes such as RAS family (124).

Figure 1. Endoscopic image of sigmoid colon of familial adenomatous polyposis (FAP) patient

FAP is one of the best defined hereditary cancers that account less than 1% of all CRC incidences. Small abnormalities (develop hundreds to thousands of colorectal polyps) at the surface of the intestinal tract observed, especially in the large intestine including the colon or rectum. Untreated polyposis leads to 100% risk of cancer. If malignancy develops, this may present with weight loss. FAP can also give few or no signs until it have developed into advanced CRC. (Adapted from https://familyhistorybowelcancer.wordpress.com/tag/familial-adenomatous-polyposis/).

CIN could occur at any stage of tumor genesis. It seems that the loss of APC function plays an important role in the CIN seen in FAP. The CIN pathway results from mutations.
CIN pathway

Normal Colon cell → cells with APC mutant +/- → cells with APC mutant +/- → malignant cells → CIN 80-85% formation CRC cases

Onset of genetic Alternation growth of adenoma cells

Figure 2. CIN in FAP

A. Normal colonic epithelial cells

B. Colon cancer cells

Controlled cell growth

Uncontrolled cell growth

Figure 3. Wnt pathway in FAP

in genes that control mitosis, DNA repair, and other essential processes of DNA replication. CIN is associated with mutation in APC gene and/or lack of chromosome 5q that includes the APC gene, mutation of the KRAS oncogene, deletion of chromosome 17p and loss of chromosome 18q, which contains the important tumor suppressor gene TP53.

Within the sight of the Wnt, its receptor, Frizzled, in complex with LRP6, is actuated. Axin (Axil/conductin) binds to a complex with APC, β-Catenin, and GSK3β to advance β-Catenin phosphorylation. GSK3β controls this process via phosphorylating β-Catenin, APC and Axin (Axil/conductin) complex. Activation of the Wnt signaling pathway prevents GSK3β function and stabilizes β-Catenin. Loss of the negative Wnt pathway regulator APC takes place in the majority of colorectal cancers such as FAP. In the absence of Wnt-signaling, GSK3β and CK1 or 2 kinases become phosphorylate and active β-Catenin at serine and threonine residues within the N-terminal area. Mutations of β-Catenin or truncation of APC, which occur in FAP, increases the transcriptional activity and stability of β-Catenin. Disruption of the APC/β-Catenin pathway is proven as a crucial step in the improvement of FAP.
Familial adenomas polyp, an autosomal dominant pre-malignant disease that usually progresses to malignancy is caused by mutations in the \( \text{APC} \) TSG. This gene counteracts with \( \beta \)-Catenin activation at Wnt target genes (Frequency:85).

\( \text{Axin2} \) likely plays a significant role in the regulation of the stability of \( \beta \)-Catenin in the Wnt pathway; it forms a complex of \( \text{APC} \), \( \beta \)-Catenin, glycogen synthase kinase 3-beta (GSK3b), and conduction, which leads to the degradation of \( \beta \)-Catenin. This gene appears to act as a tumor suppressor, and somatic mutations have been seen in many different tumor types such as FAP tumors.

This gene encodes a protein which is a member of the dickkopf group. \( \text{DKK1} \) Is a secreted protein with two cysteines rich regions and is involved in embryonic improvement via its prevention of the Wnt signaling pathway.

This gene encodes a tumor suppressor protein, including transcriptional activation, oligomerization areas and DNA binding. The encoded protein responds to varying cellular stresses to control expression of target genes, therefore inducing DNA repair, senescence, apoptosis, cell cycle arrest, or alterations in metabolism. Mutations in \( \text{TP53} \) are associated with a diversity of human syndrome, such as FAP. \( \text{P53} \) expression was only slightly increased in adenomas, but more often expressed in carcinomas in FAP patients (Frequency: 35-55).

**Table 1. Tumor-suppressor genes commonly associated with FAP**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Full Name</th>
<th>Location</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \text{APC} )</td>
<td>adenomatous polyposis coli</td>
<td>5q21-q22</td>
<td>Familial adenomas polyp, an autosomal dominant pre-malignant disease that usually progresses to malignancy is caused by mutations in the ( \text{APC} ) TSG. This gene counteracts with ( \beta )-Catenin activation at Wnt target genes (Frequency:85).</td>
</tr>
<tr>
<td>( \text{Axin2} )</td>
<td>axin 2</td>
<td>17q24.1</td>
<td>( \text{Axin2} ) likely plays a significant role in the regulation of the stability of ( \beta )-Catenin in the Wnt pathway; it forms a complex of ( \text{APC} ), ( \beta )-Catenin, glycogen synthase kinase 3-beta (GSK3b), and conduction, which leads to the degradation of ( \beta )-Catenin. This gene appears to act as a tumor suppressor, and somatic mutations have been seen in many different tumor types such as FAP tumors.</td>
</tr>
<tr>
<td>( \text{DKK1} )</td>
<td>dickkopf WNT signaling pathway inhibitor 1</td>
<td>10q11.2</td>
<td>This gene encodes a protein which is a member of the dickkopf group. ( \text{DKK1} ) Is a secreted protein with two cysteines rich regions and is involved in embryonic improvement via its prevention of the Wnt signaling pathway.</td>
</tr>
<tr>
<td>( \text{TP53} )</td>
<td>tumor protein p53</td>
<td>17p13.1</td>
<td>This gene encodes a tumor suppressor protein, including transcriptional activation, oligomerization areas and DNA binding. The encoded protein responds to varying cellular stresses to control expression of target genes, therefore inducing DNA repair, senescence, apoptosis, cell cycle arrest, or alterations in metabolism. Mutations in ( \text{TP53} ) are associated with a diversity of human syndrome, such as FAP. ( \text{P53} ) expression was only slightly increased in adenomas, but more often expressed in carcinomas in FAP patients (Frequency: 35-55).</td>
</tr>
</tbody>
</table>

**Table 2. Different types of mutation in \( \text{APC} \) in FAP patients from different populations**

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Frequency (%)</th>
<th>Exon</th>
<th>Population</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>point mutations</td>
<td>80</td>
<td>--------</td>
<td>Belgian</td>
<td>(39)</td>
</tr>
<tr>
<td>micro deletions</td>
<td>60-70</td>
<td>--------</td>
<td>Balearic People</td>
<td>(47)</td>
</tr>
<tr>
<td>Frame shift</td>
<td>43</td>
<td>15</td>
<td>Rochester(Mayo clinic)</td>
<td>(52)</td>
</tr>
<tr>
<td>nonsense</td>
<td>42</td>
<td>15</td>
<td>Rochester(Mayo clinic)</td>
<td>(52)</td>
</tr>
<tr>
<td>Duplication</td>
<td>6</td>
<td>15</td>
<td>Brazilian</td>
<td>(58)</td>
</tr>
<tr>
<td>Duplication</td>
<td>6</td>
<td>15</td>
<td>Rochester(Mayo clinic)</td>
<td>(52)</td>
</tr>
<tr>
<td>large deletions</td>
<td>37.5</td>
<td>15</td>
<td>Hungary</td>
<td>(54)</td>
</tr>
<tr>
<td>large deletions</td>
<td>15</td>
<td>14</td>
<td>Belgian</td>
<td>(39)</td>
</tr>
<tr>
<td>large deletions</td>
<td>14.2</td>
<td>11,15</td>
<td>Chinese</td>
<td>(55)</td>
</tr>
<tr>
<td>large deletions</td>
<td>12.5</td>
<td>11-13</td>
<td>Swedish</td>
<td>(53)</td>
</tr>
<tr>
<td>large deletions</td>
<td>7-12</td>
<td>14</td>
<td>London</td>
<td>(56)</td>
</tr>
<tr>
<td>large deletions</td>
<td>7.3</td>
<td>4,1-15</td>
<td>Spanish</td>
<td>(51)</td>
</tr>
<tr>
<td>large deletions</td>
<td>7.57</td>
<td>14</td>
<td>Taiwanese</td>
<td>(129)</td>
</tr>
<tr>
<td>large deletions</td>
<td>6</td>
<td>14</td>
<td>Czech</td>
<td>(57)</td>
</tr>
<tr>
<td>large deletions</td>
<td>5.8</td>
<td>15</td>
<td>Iranian</td>
<td>(50)</td>
</tr>
<tr>
<td>large deletions</td>
<td>5.6</td>
<td>3,4,10-14,11-13,14-15</td>
<td>Polish</td>
<td>(40)</td>
</tr>
<tr>
<td>large deletion</td>
<td>10-15</td>
<td>15</td>
<td>Balearic People</td>
<td>(47)</td>
</tr>
<tr>
<td>large deletion</td>
<td>0</td>
<td>--------</td>
<td>Greek</td>
<td>(46)</td>
</tr>
<tr>
<td>large deletion</td>
<td>0</td>
<td>--------</td>
<td>Slovak</td>
<td>(57)</td>
</tr>
</tbody>
</table>

\*\( \text{APC} \)=adenomatous polyposis coli, \( \text{FAP} \)= familial adenomatous polyposis
The EphB2 gene is essential for cell differentiation within the intestinal stem cell. This gene is transcriptionally repressed by Wnt signaling.

SOX9

It is essential for cell differentiation within the intestinal stem cell. This gene is transcriptionally repressed by Wnt signaling.

Tumor suppressor genes in familial adenomatous polyposis

Table 3. Wnt/β-Catenin Target Genes in FAP

<table>
<thead>
<tr>
<th>Gene</th>
<th>Comment</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>APC</td>
<td>the most commonly mutated gene in Wnt pathway in FAP</td>
<td>(15, 65)</td>
</tr>
<tr>
<td>AXIN2</td>
<td>The AXIN2 plays an important role in the adjustment of the stability of β-Catenin in the Wnt pathway</td>
<td>(81)</td>
</tr>
<tr>
<td>TCF7L2</td>
<td>This gene is a key effector for Wnt pathway, and the bipartite transcription factor TCF / β-Catenin, is provided by free β-Catenin and a TCF protein, including TCF7L2</td>
<td>(35, 64, 77-79)</td>
</tr>
<tr>
<td>NDK1</td>
<td>regulate the Wnt signaling pathway</td>
<td>(84, 85)</td>
</tr>
<tr>
<td>SOX9</td>
<td>It is essential for cell differentiation within the intestinal stem cell. This gene is transcriptionally repressed by Wnt signaling</td>
<td>(83)</td>
</tr>
<tr>
<td>EphB2</td>
<td>The EphB2 encodes the Eph receptor B, that reported to be a target of the Wnt signaling pathway</td>
<td>(65, 80)</td>
</tr>
</tbody>
</table>

References

Aghdaei HA. Novel missense mutation at codon 2774 (C.8321
G> A) p. S2774N of APC gene in a Denovo case of familial

Farahani RK, Haghighi MM, Aghdaei HA, Keshavarzi F,
González S, Blanco I, Campos O, Julià M, Reyes J, Llompart A,
Fostira F, Thodi G, Sandaltzopoulos R, Fountzilas G, Yannoukakos
Su LK, Kohlmann W, Ward PA, Lynch PM. Different familial
polyposis in unrelated Korean patients with FAP: four novel mutations with unusual phenotype. Fam Cancer

Heinen CD. Genotype to phenotype: analyzing the effects of
inherited mutations in familial colorectal cancer families. Mutat Res 2010; 693: 32-45.

Martayan A, Sanchez-Mete L, Baldelli R, Falvo E, Barnabei
A, Conti L, et al. Gene variants associated to malignant thyroid

Michlis G, Tejpar S, Thoelen R, Cutsen Ev, Vermeesch JR, Fryns
JP, et al. Large deletions of the APC gene in 15% of mutation-

Plawski A, Slomski R. APC gene mutations causing familial
adenomatous polyposis in Polish patients. J Appl Genet 2008; 49:
407-14.

Gavert N, Yaron Y, Naiman T, Bercovich D, Rozen P, Shomrat R,
et al. Molecular analysis of the APC gene in 71 Israeli families: 17

Rosa MD, Scarano MI, Panariello L, Morelli G, Riegler G, Rossi
GB, et al. Contribution of APC and MUTYH mutations to familial
adenomatous polyposis susceptibility in Hungary. Fam Cancer

Sheng JQ, Cui WJ, Fu L, Jin P, Han Y, Li SJ, et al. APC gene
mutations in Chinese familial adenomatous polyposis patients.

Sieber O, Lamllum H, Crabtree M, Rowan A, Barclay E, Lipton
L, et al. Whole-gene APC deletions cause classical familial
adenomatous polyposis, but not attenuated polyposis or “multiple”

8: 16.

Torrezan GT, da Silva FCC, Santos EM, Krepitchi ACV, Achatz
MIW, Junior SA, et al. Mutation spectrum of the APC and
MUTYH genes and genotype-phenotype correlations in Brazilian
FAP, AFAP, and MAP patients. Orphanet J Rare Dis 2013; 8: 54.

Lipton L, Tomlinson I. The genetics of FAP and FAP-like syndromes. Fam Cancer 2006; 5: 221-6.

Ruiz-Ponte C, Vega A, Carracedo A, Barros F. Mutation analysis of
the adenomatous polyposis coli (APC) gene in northwest Spanish patients with familial adenomatous polyposis (FAP) and

Schlussel AT, Donlon SS, Eggering FA, Gagliano RA. Identification of an APC variant in a patient with clinical
attenuated familial adenomatous polyposis. Case Rep Med 2014;
2014: 432324.

Sierra J, Yoshida T, Jouzeiro CA, Jones KA. The APC tumor suppressor counteracts β-catenin activation and H3K4 methylation

Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt
RW. ACG clinical guideline: Genetic testing and management of
hereditary gastrointestinal cancer syndromes. Am J Gastroenterol

Najdi R, Holcombe RF, Waterman ML. Wnt signaling and colon

Schneickt J, Behrens J. The canonical Wnt signalling pathway
and its APC partner in colon cancer development. Gut 2007; 56:
417-25.

Rao CV, Yamada HY. Genomic instability and colon
carcinogenesis: from the perspective of genes. Front Oncol 2013;
3: 130.

Alberici P, de Pater E, Cardoso J, Bevelander M, Molenaar L,
Jonkers J, et al. Aneuploidy arises at early stages of APC-driven
intestinal tumorigenesis and pinpoints conserved chromosomal
loci of allelic imbalance between mouse and human. Am J Pathol

Arvelo F, Sojo F, Cote C. Biology of colorectal cancer.


Eshghifar N, et al.
Ecmafmedicalscience 2015; 9: 520.


